Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 881 to 890 of 1557 total matches.
Influenza Vaccines for 2025-2026
The Medical Letter on Drugs and Therapeutics • Sep 29, 2025 (Issue 1738)
the risk of influenza-related
hospitalization and death.11-13
The Medical Letter ® Vol. 67 (1738 ...
Annual vaccination against influenza A and B viruses
is recommended in the US for everyone ≥6 months
old without a contraindication. Influenza vaccines
available in the US for the 2025-2026 season are listed
in Table 2.
Med Lett Drugs Ther. 2025 Sep 29;67(1738):153-8 doi:10.58347/tml.2025.1738a | Show Introduction Hide Introduction
Drugs for Common Bacterial Infections in Adults
The Medical Letter on Drugs and Therapeutics • Oct 23, 2017 (Issue 1532)
of streptococcal pharyngitis.
The Medical Letter ® Vol. 59 (1532) October 23, 2017
considered for adults who ...
Bacterial infections in adults are generally treated
empirically, with the antibiotic covering most, but not
all, of the potential causative pathogens. For some
infections, culture and sensitivity testing can guide
treatment, allowing for use of narrower-spectrum
antibiotics. The recommended dosages and durations
of antibiotic treatment for common respiratory, skin, and
urinary tract infections are listed in Tables 1-3. Infectious
disease experts now recommend shorter treatment
durations for many infections to reduce the development
of antimicrobial resistance and minimize adverse...
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
by methotrexate.
The Medical Letter ® Vol. 63 (1637) November 15, 2021
Table 1. Some Conventional DMARDs ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Drugs for GERD and Peptic Ulcer Disease
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022 (Issue 1647)
completion of therapy.
The Medical Letter ® Vol. 64 (1647) April 4, 2022
50
recommended. PPIs decrease ...
Gastroesophageal reflux disease (GERD) is the most
common GI condition encountered in the outpatient
setting; it affects about 20% of people in the US.
Drugs for Opioid Use Disorder
The Medical Letter on Drugs and Therapeutics • Sep 04, 2023 (Issue 1684)
Letter ® Vol. 65 (1684) September 4, 2023
138
Table 1. Drugs for Maintenance Treatment of Opioid Use ...
Opioid use disorder is a chronic, relapsing disease with
physical and psychiatric components. It is associated
with economic hardship, social isolation, incarceration,
increased rates of blood-borne infections such as HIV
and viral hepatitis, adverse pregnancy outcomes, and
increased mortality. According to the NIH, there were
80,411 deaths involving an opioid in the US in 2021,
more than in any previous year. Several guidelines on
the management of opioid use disorder are available;
all recommend maintenance pharmacotherapy as the
standard of care.
Med Lett Drugs Ther. 2023 Sep 4;65(1684):137-44 doi:10.58347/tml.2023.1684a | Show Introduction Hide Introduction
Drugs for Plaque Psoriasis
The Medical Letter on Drugs and Therapeutics • Sep 30, 2024 (Issue 1712)
involving the face and intertriginous areas. The Medical Letter ® Vol. 66 (1712) September 30, 2024
154 ...
Mild to moderate plaque psoriasis can be treated
with topical drugs and phototherapy. Patients
with moderate to severe disease generally require
systemic therapy. Guidelines for the treatment of
psoriasis with topical therapy, phototherapy, and
systemic drugs have recently been published.
Med Lett Drugs Ther. 2024 Sep 30;66(1712):153-60 doi:10.58347/tml.2024.1712a | Show Introduction Hide Introduction
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025 (Issue 1734)
to achieve weight loss of
The Medical Letter ® Vol. 67 (1734) August 4, 2025
at least 10% (81.6% vs 60.5 ...
Overweight is generally defined as a body mass
index (BMI) between 25 and 29.9 kg/m2 in adults. A
BMI ≥30 is considered obese (criteria differ slightly in
Asian patients). In patients with an elevated BMI, a
5-10% reduction in weight has been associated with
a reduction in the risk of developing type 2 diabetes,
hypertension, and dyslipidemia. Diet, exercise, and
behavior modification are the traditional methods
for losing weight, but they are often inadequate; the
American College of Cardiology no longer recommends
that all patients try lifestyle modification alone before
adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8 doi:10.58347/tml.2025.1734a | Show Introduction Hide Introduction
The Viralizer For The Common Cold
The Medical Letter on Drugs and Therapeutics • Jan 27, 1989 (Issue 784)
SITE: http://www.medletter.com
The Medical Letter, Vol. 31 (Issue 784) January 27, 1989, p. 8 ...
Recently, full-page advertisements have appeared in the New York Times and other newspapers promoting the Viralizer (Viral Response Systems, Greenwich, CT), a heated nebulizer-sprayer device marketed for treatment of colds, sore throats, allergy and sinusitis symptoms. The device is available without a prescription for about $30 to $40.
Isosorbide Mononitrate for Angina
The Medical Letter on Drugs and Therapeutics • Jun 26, 1992 (Issue 873)
The Medical Letter, Vol. 34 (Issue 873) June 26, 1992, p. 61
Copyright The Medical Letter
UNAUTHORIZED ...
Isosorbide mononitrate (ISMN; Ismo - Wyeth-Ayerst), an oral nitrate long available in Europe, was recently approved by the US Food and Drug Administration for prophylactic use in patients with chronic stable angina. ISMN is the major active metabolite of isosorbide dinitrate (ISDN; Isordil, and others).
Desflurane - A New Volatile Anesthetic
The Medical Letter on Drugs and Therapeutics • Apr 30, 1993 (Issue 895)
://www.medletter.com
The Medical Letter, Vol. 35 (Issue 895) April 30, 1993, pp. 38
Copyright The Medical Letter ...
Desflurane (Suprane - Anaquest), an inhalation anesthetic, has been approved by the US Food and Drug Administration for induction and maintenance of general anesthesia in adults and for maintenance of anesthesia in infants and children. Like isoflurane (Forane), the last volatile anesthetic to become available in the USA (Medical Letter, 23:112, 1981), the new agent is a halogenated methyl ethyl ether, differing from isoflurane in the substitution of a fluorine for a chlorine atom.